BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

...Founders Fund and Gaingels, plus existing investors Luma Bio-IT, Alexandria Venture Investments and Ulysses Diversified Holdings.Eloxx...
...the same role at Eloxx; Vijay Modur, Zikani’s chief scientific and medical officer, will be Eloxx’s...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

...part of the senior executive team at Amal Therapeutics S.A., which Boehringer Ingelheim GmbH acquired. Eloxx...
...royalty interests. BioCentury Staff Halozyme Therapeutics Inc. Adverum Biotechnologies Inc. Aurinia Pharmaceuticals Inc. Neoleukin Therapeutics Inc. Arena Pharmaceuticals Inc. Insilico Medicine Inc. Nouscom AG Eloxx...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:MDCO) 6/25/19 $172.5 $2,616.2 $2,891.3 11% Krystal Biotech Inc. (NASDAQ:KRYS) 6/24/19 $100.0 $677.7 $682.3 1% Eloxx...
BioCentury | Oct 26, 2018
Financial News

First close for China Everbright’s new healthcare fund

...billion). China Everbright's portfolio includes bioconjugate company Ambrx Inc. (La Jolla, Calif.), genetic disease company Eloxx...
BioCentury | Oct 23, 2018
Financial News

First close for China Everbright’s new healthcare fund

...billion). China Everbright's portfolio includes bioconjugate company Ambrx Inc. (La Jolla, Calif.), genetic disease company Eloxx...
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...Inc. (Cambridge, Mass.) hired Pedro Huertas as CMO. He was CMO at rare disease company Eloxx...
BioCentury | Jun 28, 2018
Company News

Management tracks: Arrakis, Astellas

...at the Japanese Novartis Pharma K.K. unit of Novartis AG (NYSE:NVS; SIX:NOVN). Genetic disease company Eloxx...
BioCentury | Jun 18, 2018
Company News

Management tracks: Ionis, Albireo

...as general counsel. He was general counsel at Stallergenes Greer plc (Euronext:STAGR). Rare disease company Eloxx...
BioCentury | May 18, 2018
Finance

China comes to Europe

...of Hong Kong; (B) In December 2017, Eloxx Pharmaceuticals Ltd. reverse-merged with Sevion Therapeutics, Inc. to form Eloxx...
...Ventures, Shavit Capital, Israel Biotech Fund, VMS Investment Group Cell therapy Hematological diseases, including cancer Eloxx Pharmaceuticals Ltd....
BioCentury | Apr 27, 2018
Financial News

Rare disease company Eloxx raises $50M, lists on NASDAQ

...Rare and ultra-rare premature stop codon diseases company Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) raised $50 million in...
...offering. Previously, Eloxx traded on the over-the-counter exchange. Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX), Waltham, Mass. Jaime De Leon Eloxx...
Items per page:
1 - 10 of 16
BioCentury | Apr 3, 2021
Deals

April 2 Quick Takes: Agios begins share buybacks upon closing Servier deal, plus Royalty-GSK, Gracell-Lonza, Alloy, Eloxx-Zikani and Angelini-Ovid

...Founders Fund and Gaingels, plus existing investors Luma Bio-IT, Alexandria Venture Investments and Ulysses Diversified Holdings.Eloxx...
...the same role at Eloxx; Vijay Modur, Zikani’s chief scientific and medical officer, will be Eloxx’s...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

...part of the senior executive team at Amal Therapeutics S.A., which Boehringer Ingelheim GmbH acquired. Eloxx...
...royalty interests. BioCentury Staff Halozyme Therapeutics Inc. Adverum Biotechnologies Inc. Aurinia Pharmaceuticals Inc. Neoleukin Therapeutics Inc. Arena Pharmaceuticals Inc. Insilico Medicine Inc. Nouscom AG Eloxx...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:MDCO) 6/25/19 $172.5 $2,616.2 $2,891.3 11% Krystal Biotech Inc. (NASDAQ:KRYS) 6/24/19 $100.0 $677.7 $682.3 1% Eloxx...
BioCentury | Oct 26, 2018
Financial News

First close for China Everbright’s new healthcare fund

...billion). China Everbright's portfolio includes bioconjugate company Ambrx Inc. (La Jolla, Calif.), genetic disease company Eloxx...
BioCentury | Oct 23, 2018
Financial News

First close for China Everbright’s new healthcare fund

...billion). China Everbright's portfolio includes bioconjugate company Ambrx Inc. (La Jolla, Calif.), genetic disease company Eloxx...
BioCentury | Oct 2, 2018
Company News

Management tracks: Synlogic, Trevena, Editas

...Inc. (Cambridge, Mass.) hired Pedro Huertas as CMO. He was CMO at rare disease company Eloxx...
BioCentury | Jun 28, 2018
Company News

Management tracks: Arrakis, Astellas

...at the Japanese Novartis Pharma K.K. unit of Novartis AG (NYSE:NVS; SIX:NOVN). Genetic disease company Eloxx...
BioCentury | Jun 18, 2018
Company News

Management tracks: Ionis, Albireo

...as general counsel. He was general counsel at Stallergenes Greer plc (Euronext:STAGR). Rare disease company Eloxx...
BioCentury | May 18, 2018
Finance

China comes to Europe

...of Hong Kong; (B) In December 2017, Eloxx Pharmaceuticals Ltd. reverse-merged with Sevion Therapeutics, Inc. to form Eloxx...
...Ventures, Shavit Capital, Israel Biotech Fund, VMS Investment Group Cell therapy Hematological diseases, including cancer Eloxx Pharmaceuticals Ltd....
BioCentury | Apr 27, 2018
Financial News

Rare disease company Eloxx raises $50M, lists on NASDAQ

...Rare and ultra-rare premature stop codon diseases company Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) raised $50 million in...
...offering. Previously, Eloxx traded on the over-the-counter exchange. Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX), Waltham, Mass. Jaime De Leon Eloxx...
Items per page:
1 - 10 of 16